Table 1 Baseline clinical, biochemical and pathological features of the cohort
Parameters | Value |
|---|---|
Clinical: | |
Cohort total number of patients: | 1425 |
Age at diagnosis, years, mean (SD): | 68.6 (8.72) |
Age categories, n (%) | |
- < 50 years | 8 (0.6%) |
- 50–74 years | 861 (60.4%) |
- ≥75 years | 556 (39%) |
Baseline prostate volume (ml3), median [IQR]: | 36.4 [27–49.8] |
Clinical stage: n (%) | |
- T1-2a | 859 (60.3%) |
- T2b | 355 (24.9%) |
- T2c-3a | 211 (14.8%) |
Biochemical: | |
Baseline PSA (ng/ml), median [IQR] | 7.55 [5.4–12] |
PSA categories, ng/ml, n (%) | |
- ≤ 4: | 113 (7.9%) |
- 4.1–10: | 835 (58.6%) |
- 10.1–20: | 293 (20.6%) |
- > 20 | 184 (12.9%) |
PSA density (ng/ml/ml3), median [IQR] | 0.21 [0.13–0.36] |
Pathological: | |
Gleason score, n (%) | |
- Gleason ≤6: | 566 (39.7%) |
- Gleason 7: | 473 (33.2%) |
- Gleason 8: | 194 (13.6%) |
- Gleason 9: | 168 (11.8%) |
- Gleason 10: | 24 (1.7%) |
D’Amico risk classification, n (%) | |
- Low: | 477 (33.4%) |
- Intermediate: | 503 (35.3%) |
- High | 445 (31.2%) |